BR112012002064A2 - método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele - Google Patents
método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando deleInfo
- Publication number
- BR112012002064A2 BR112012002064A2 BR112012002064A BR112012002064A BR112012002064A2 BR 112012002064 A2 BR112012002064 A2 BR 112012002064A2 BR 112012002064 A BR112012002064 A BR 112012002064A BR 112012002064 A BR112012002064 A BR 112012002064A BR 112012002064 A2 BR112012002064 A2 BR 112012002064A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- tumor
- treatment
- need
- obtaining
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23059509P | 2009-07-31 | 2009-07-31 | |
US34644410P | 2010-05-19 | 2010-05-19 | |
US35102210P | 2010-06-03 | 2010-06-03 | |
PCT/US2010/043992 WO2011014821A1 (en) | 2009-07-31 | 2010-07-30 | Folate-targeted diagnostics and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012002064A2 true BR112012002064A2 (pt) | 2017-05-09 |
Family
ID=43529728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012002064A BR112012002064A2 (pt) | 2009-07-31 | 2010-07-30 | método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele |
Country Status (13)
Country | Link |
---|---|
US (2) | US20120128587A1 (pt) |
EP (1) | EP2460013A4 (pt) |
JP (1) | JP2013501224A (pt) |
KR (1) | KR20120050462A (pt) |
CN (2) | CN102549434A (pt) |
AU (1) | AU2010278734A1 (pt) |
BR (1) | BR112012002064A2 (pt) |
CA (1) | CA2769754A1 (pt) |
IL (1) | IL217744A0 (pt) |
IN (1) | IN2012DN01708A (pt) |
NZ (1) | NZ598145A (pt) |
RU (1) | RU2012105641A (pt) |
WO (1) | WO2011014821A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3388086B1 (en) | 2007-08-17 | 2020-10-07 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
EA026168B1 (ru) * | 2010-11-12 | 2017-03-31 | Эндосайт, Инк. | Способы лечения рака |
SG194458A1 (en) * | 2011-04-12 | 2013-12-30 | Endocyte Inc | Solid pharmaceutical composition |
EP3875082A1 (en) | 2012-11-15 | 2021-09-08 | Endocyte, Inc. | Conjugates for treating diseases caused by psma expressing cells |
US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
JP6595463B2 (ja) | 2013-10-16 | 2019-10-23 | ユニベルシテ リブレ デ ブリュッセル | 気道に影響する増殖性疾患の処置に有用な製剤 |
EP4095130B1 (en) | 2013-10-18 | 2024-01-31 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
EP3071971B1 (en) | 2013-11-19 | 2019-04-24 | Purdue Research Foundation | Patient selection method for inflammation |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US20170368208A1 (en) * | 2015-01-11 | 2017-12-28 | Endocyte, Inc. | Cancer imaging agent |
CN110678204A (zh) * | 2016-03-29 | 2020-01-10 | 恩多塞特公司 | 用于靶向肿瘤相关巨噬细胞的叶酸缀合物 |
WO2017192863A1 (en) | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
KR102489277B1 (ko) * | 2016-05-25 | 2023-01-16 | 퍼듀 리서치 파운데이션 | 골수-유래 억제 세포를 표적화함으로써 암을 치료하는 방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2512867C (en) * | 2003-01-27 | 2014-08-26 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
ES2357089T5 (es) * | 2004-12-21 | 2014-02-24 | Nektar Therapeutics | Reactivos de tiol polimérico estabilizados |
EP1827239B1 (en) * | 2004-12-23 | 2019-04-17 | Purdue Research Foundation | Positron emission tomography imaging method |
JP5289935B2 (ja) * | 2005-03-16 | 2013-09-11 | エンドサイト,インコーポレイテッド | プテロイン酸およびその結合体の合成と精製 |
EP2199796A1 (en) * | 2005-03-30 | 2010-06-23 | Endocyte, Inc. | Method for cancer prognosis using cellular folate vitamin receptor quantification |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
EP2076259A2 (en) * | 2006-10-25 | 2009-07-08 | Schering Corporation | Methods of treating ovarian cancer |
JP5690589B2 (ja) * | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
-
2010
- 2010-07-30 CN CN2010800434602A patent/CN102549434A/zh active Pending
- 2010-07-30 US US13/388,184 patent/US20120128587A1/en not_active Abandoned
- 2010-07-30 AU AU2010278734A patent/AU2010278734A1/en not_active Abandoned
- 2010-07-30 NZ NZ598145A patent/NZ598145A/en not_active IP Right Cessation
- 2010-07-30 RU RU2012105641/15A patent/RU2012105641A/ru not_active Application Discontinuation
- 2010-07-30 IN IN1708DEN2012 patent/IN2012DN01708A/en unknown
- 2010-07-30 CN CN201510160314.2A patent/CN104857534A/zh active Pending
- 2010-07-30 WO PCT/US2010/043992 patent/WO2011014821A1/en active Application Filing
- 2010-07-30 JP JP2012523104A patent/JP2013501224A/ja active Pending
- 2010-07-30 CA CA2769754A patent/CA2769754A1/en not_active Abandoned
- 2010-07-30 KR KR1020127005358A patent/KR20120050462A/ko not_active Application Discontinuation
- 2010-07-30 BR BR112012002064A patent/BR112012002064A2/pt not_active IP Right Cessation
- 2010-07-30 EP EP10805137A patent/EP2460013A4/en not_active Withdrawn
-
2012
- 2012-01-26 IL IL217744A patent/IL217744A0/en unknown
-
2013
- 2013-03-13 US US13/800,309 patent/US20140140925A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2013501224A (ja) | 2013-01-10 |
CN102549434A (zh) | 2012-07-04 |
US20140140925A1 (en) | 2014-05-22 |
IN2012DN01708A (pt) | 2015-06-05 |
CA2769754A1 (en) | 2011-02-03 |
EP2460013A4 (en) | 2013-04-03 |
AU2010278734A1 (en) | 2012-02-23 |
IL217744A0 (en) | 2012-03-29 |
RU2012105641A (ru) | 2013-09-10 |
WO2011014821A1 (en) | 2011-02-03 |
NZ598145A (en) | 2014-10-31 |
EP2460013A1 (en) | 2012-06-06 |
KR20120050462A (ko) | 2012-05-18 |
US20120128587A1 (en) | 2012-05-24 |
CN104857534A (zh) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012002064A2 (pt) | método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele | |
Lennon et al. | Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis | |
Bernier et al. | Molecular therapy in head and neck oncology | |
Li et al. | Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC) | |
Gautier et al. | New insights into pharmacological tools to TR (i) P cancer up | |
Freeman et al. | Effect of perioperative lidocaine and cisplatin on metastasis in a murine model of breast cancer surgery | |
Lin et al. | Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis | |
FR2896881B1 (fr) | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie | |
Sharma et al. | Alveolar macrophage activation in obese patients with obstructive sleep apnea | |
EA201070725A1 (ru) | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона | |
Yeh et al. | Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction | |
Nie et al. | Synergistic interaction between dexmedetomidine and ulinastatin against vincristine-induced neuropathic pain in rats | |
Garg et al. | Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters | |
Pedersini et al. | Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study | |
Gervais et al. | Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer | |
Lin et al. | Update on the role of neuropeptide Y and other related factors in breast cancer and osteoporosis | |
Belyaeva et al. | Application of laser phoresis in complicated postmenopausal osteoporosis | |
Zhao et al. | Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3 | |
Li et al. | Ginsenoside (20S)-protopanaxatriol induces non-protective autophagy and apoptosis by inhibiting Akt/mTOR signaling pathway in triple-negative breast cancer cells | |
Shibuya et al. | Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-ĸB, and VEGF in oral squamous cell carcinoma | |
MP | Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor | |
Liu et al. | Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma | |
Rahal et al. | Implications and efficacy of aromatase inhibitors in combination and monotherapy for the treatment of lung cancer | |
WO2019100003A1 (en) | Combination therapy targeting cancer associated with the hedgehog pathway | |
Spiegelberg et al. | The novel anti-cMet antibody seeMet 12 potentiates sorafenib therapy and radiotherapy in a colorectal cancer model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |